Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Enterin is raising $19,999,941.00 in new funding. Sources indicate as part of senior management President, Denise Barbut played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Enterin

Enterin is pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease.

To learn more about Enterin, visit http://enterininc.com/

Contact:
Denise Barbut, President
617-832-1767
d.barbut@enterininc.com
https://www.linkedin.com/in/denise-barbut-md-frcp-9257a114/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved